Endocrine Abstracts

Background: An activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common observation in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in obesity, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY 3-36), might be also useful for the treatment of obesity. However, the effect of these substances on the adrenal gland is largely unknown. We directly compared the effec...

Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity of obesity. In this study, we sought to determine hepatic metabolic and mitochondrial effects of the Glucagon-like Peptide-1-agonist semaglutide, the sodium-glucose linked transporter 2-inhibitor empagliflozin and Peptide YY3-36 in diet-induced obese rats with additional chronic inhibition of nitric oxide synthase via Nω-nitro-L-arginine meth...

Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently accompanies obesity, posing a significant health concern. The Neuropeptide Y (NPY) system, a key player in energy metabolism regulation, has implications for liver health, yet the impact of NPY receptor antagonists remains largely unexplored. This study investigates the effects of antagonists targeting the NPY-2 receptor (Y2R) in comparison to known MASLD-beneficial substances.Me...

Background: The crosstalk between the adrenal gland and different fat depots is largely unknown. As primary hyperaldosteronism leads to an increased risk of cardiovascular disease and associated pathologies (glucose intolerance, diabetes, hyperlipidemia), elucidating the interaction between aldosterone producing adenomas (APAs) and different fat depots might help to understand causality and open new diagnostic and treatment strategies.Methods: Subcutaneo...